Sinovac's Financial Performance in Early 2024
In the first half of 2024, Sinovac Biotech Ltd. experienced a notable downturn in its financial performance. The company's revenues fell to $121.3 million, a decrease from $140.4 million in the same period of the previous year. This decline in revenue was accompanied by a net loss of $10.9 million, a significant shift from the $14.0 million net income reported last year.
Exclusive Access: Unlock Premium, Confidential Insights
Unlock This Exclusive Content—Subscribe Instantly!
Login if you have purchased
